Company Description
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States.
It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.
The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease.
In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina.
Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain.
It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.
| Country | Canada |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Dr. Isa Odidi MBA, Ph.D. |
Contact Details
Address: 30 Worcester Road Toronto, A6 M9W 5X2 Ontario, Canada | |
| Phone | 416-798-3001 |
| Website | intellipharmaceutics.com |
Stock Details
| Ticker Symbol | IPCIF |
| Exchange | OTCMKTS |
| Fiscal Year | December - November |
| Reporting Currency | USD |
| CIK Code | 0001474835 |
| CUSIP Number | 458173309 |
| ISIN Number | CA4581733090 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Isa Odidi MBA, Ph.D. | Co-Founder, Chairman of the Board, Chief Executive Officer and Co-Chief Scientific Officer |
| Dr. Amina Odidi Ph.D. | President, Chief Operating Officer, Co-Chief Scientific Officer, Acting Chief Financial Officer and Executive Director |
| Dr. Patrick N. Yat Ph.D. | Vice-President of Chemistry and Analytical Services |
| Fazayill Shaideen | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 3, 2024 | NT 20-F | Notification of inability to timely file Form 20-F |
| Mar 14, 2024 | 6-K | Report of foreign issuer |
| Mar 7, 2024 | 6-K | Report of foreign issuer |
| Feb 27, 2024 | 6-K | Report of foreign issuer |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | UPLOAD | Filing |
| Feb 9, 2024 | 6-K | Report of foreign issuer |
| Feb 6, 2024 | 20-F/A | Filing |
| Jan 12, 2024 | 6-K | Report of foreign issuer |
| Oct 16, 2023 | 6-K | Report of foreign issuer |